Advanced search

News (116)

Novartis Eyes Sale of Listed Unit in India	03-22	CI
AI buzzes Davos, but CEOs wrestle with how to make it pay	01-17	RE
Novartis drops pursuit of Cytokinetics - source	01-11	RE
Novartis : Financial Results – Q3 2023	23-10-24	PU
Novartis AG : Sandoz takes its first steps on the stock exchange	23-10-04
What happens when a $2 million gene therapy is not enough	23-08-12	RE
Novartis Seeks M&A	23-04-25	CI
Novartis Seeks M&A	23-01-09	CI
Novartis : Financial Results – Q3 2022	22-10-25	PU
Novartis to Seek Acquisitions	22-09-22	CI
Novartis : Amendment to Annual Report by Foreign Issuer (Form 20-F/A)	22-04-26	PU
Novartis Seeks Bolt-On Acquisitions	22-02-01	CI
Transcript : Novartis AG Presents at Co-Creating Impact Summit, Dec-02-2021	21-12-02
NBC Universal : CNBC to Host First Ever “Evolve Global Summit” on June 16	21-06-03	PU
Novartis : Annual Review 2020	21-01-26	PU
Transcript : Novartis AG, Q4 2019 Earnings Call, Jan 29, 2020	20-01-29
Cboe Global Markets : Progenics To Sends Letter To Shareholders, Urges Vote For WHITE Proxy Card	19-06-13	PU
Progenics to Mail Letter to Shareholders	19-06-13	GL
Transcript : Novartis AG, Q4 2018 Earnings Call, Jan 30, 2019	19-01-30
Novartis : rises to second place in 2018 Access to Medicine Index	18-11-20	GL
Transcript : Genmab A/S Presents at Goldman Sachs 39th Annual Global Healthcare Conference, Jun-12-2018 04:00 PM	18-06-12
Novartis : readies to auction U.S. generic pills business - sources	18-02-16	RE
Novartis : appoints Elizabeth Barrett as Oncology Head	18-01-11	GL
Transcript : Novartis AG - Special Call	17-11-13
Moncef Slaoui Joins Medicxi	17-09-19	BU
Fiat Chrysler Automobiles : European shares slip on worries over North Korea nuclear test	17-09-04	RE
Novartis AG Announces Executive Changes	17-09-04	CI
Novartis : announces CEO Joseph Jimenez to retire from in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018.	17-09-04	GL
Novartis : NEJM publishes full analysis of Rydapt® (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)	17-06-23	GL
Novartis : presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting	17-06-08	GL
Novartis : ' new analyses reinforce the potential of Ultibro® Breezhaler® for COPD patients historically treated with steroids	17-05-23	GL
Novartis : NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment improves responses in severe aplastic anemia	17-04-19	GL
Novartis : to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indications	17-04-06	GL
Novartis : New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes	17-03-20	PU
Novartis : New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes	17-03-18	GL
Novartis : invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disorders	17-01-16	PU
Novartis : invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disorders	17-01-06	GL
Novartis reaches agreement to buy Texas-based Encore Vision	16-12-20	RE
Novartis : bolsters ophthalmology pipeline through acquisition of Encore Vision, Inc.	16-12-20	GL
Novartis : announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseases	16-12-19	GL
Novartis : says buys Ziarco Group to expand skin care portfolio	16-12-16	RE
Novartis : bolsters innovative dermatology portfolio through acquisition of Ziarco Group Limited	16-12-16	GL
Novartis : provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD)	16-12-12	GL
Novartis : ' Ultibro® Breezhaler® improved lung function and COPD symptoms after direct switch from previous treatment	16-12-08	GL
Novartis : commends publication of major report which recommends broad use of dual bronchodilators to treat COPD	16-11-21	GL

123NextSee all

Companies (3)

B-RIGHT REALESTATE LIMITED 20 M $

B-Right RealEstate Limited is an India-based integrated construction and real estate development company. The Company is engaged in the business of real estate development and investment. It is focused primarily on construction and development of resident ...

KBC GLOBAL LIMITED 23 M $

KBC Global Limited is an India-based company that is engaged in the business of real estate development and construction contracts. The Companyâs segments include Development of Real Estate Property and Civil Contracting Business. Its real estate develo ...

THE GREAT EASTERN SHIPPING COMPANY LIMITED 1 867 M $

The Great Eastern Shipping Company Limited is an India-based private sector shipping company. The Company provides for transportation of crude oil, petroleum products, gas and dry bulk commodities. The Company is engaged in shipping business segment. The ...

Insiders

Vasant Narasimhan

Vasant Narasimhan occupies the position of Chief Executive Officer at Novartis AG and Chief Executive Officer of Novartis International AG (a subsidiary of Novartis AG). He is also on the board of Novartis Foundation and Member of Institute of Medicine, Member of National Academy of Medicine of United States and Treasurer & Director at Pharmaceutical Research & Manufacturers of America. In his past career he occupied the position of President of Novartis Vaccines & Diagnostics, Inc., Global Head-Development at Novartis Vaccines & Diagnostics, Inc., Global Head-Development at Novartis Pharmaceuticals and Global Head-Development at Sandoz Pharmaceuticals AG. He received a graduate degree from Harvard Medical School, a graduate degree from Harvard Kennedy School of Government and an undergraduate degree from The University of Chicago.

Shankar Narasimhan

Shankar Narasimhan is the founder of GyanData Pvt Ltd.
founded in 2011, where he holds the title of Director.
Currently, he is an Independent Non-Executive Director at TANFAC Industries Ltd.
since 2007 and a Professor at Indian Institute of Technology Madras.
Previously, he was an Associate Professor at Indian Institute of Technology Kanpur.
Dr. Narasimhan's education includes a graduate and doctorate degree from Northwestern University in 1987 and an undergraduate degree from Indian Institute of Technology Madras in 1982.

Narayanan Narasimhan is currently the Non-Independent Non-Executive Chairman of Source Natural Foods & Herbal Supplements Ltd.
He is also a Director at Sumeru Ayurveda Pvt Ltd.
and Sriveda Sattva Pvt Ltd.
Additionally, he is an Associate Member of the Indian Institute of Architects and a Member of the Council of Architecture.
He is also a Partner at Sumeru Travel Solutions LLP, Divine Services Pvt Ltd., and Arvind Exports.
Narasimhan completed his undergraduate degree from the University of Madras in 1969.

Narasimhan Krishnan

Narasimhan Krishnan is currently a Director at Kaundinya Bharadwaj Electronics Pvt Ltd.
He was previously an Independent Non-Executive Director at Ecoboard Industries Ltd.
from 2011 to 2017.
He obtained his undergraduate degree from the University of Madras in 1962.

Anand Narasimhan

No results for this search

Stock Market
Advanced search
Vasant Narasimhan